Literature DB >> 10169627

Long-term survival experience of patients with multiple sclerosis.

R J Pokorski1.   

Abstract

BACKGROUND: Long-term survival of patients with multiple sclerosis is not well characterized because this disorder is relatively uncommon and subjects must be followed for decades after onset of symptoms. This paper reports comparative mortality experience of the world's largest series on an unselected cohort with multiple sclerosis.
RESULTS: Excess mortality varied with age, gender, duration since onset and diagnosis, calender year of onset, and clinical severity.
CONCLUSIONS: Compared to the general population in Denmark, patients with multiple sclerosis had less favorable survival experience during long-term follow-up.

Entities:  

Mesh:

Year:  1997        PMID: 10169627

Source DB:  PubMed          Journal:  J Insur Med        ISSN: 0743-6661


  9 in total

1.  A randomized double-blind trial of comparative efficacy and safety of Avonex and CinnoVex for treatment of relapsing-remitting multiple sclerosis.

Authors:  Hossein Pakdaman; Mehdi Abbasi; Koroush Gharagozli; Farzad Ashrafi; Hosein Delavar Kasmaei; Ali Amini Harandi
Journal:  Neurol Sci       Date:  2018-08-31       Impact factor: 3.307

2.  Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.

Authors:  Moogeh Baharnoori; Virender Bhan; Fraser Clift; Kimberly Thomas; Soukaïna Mouallif; Nicholas Adlard; Philip Cooney; François Blanchette; Barkha P Patel; Daniel Grima
Journal:  Pharmacoecon Open       Date:  2022-09-15

3.  Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Authors:  Ray Gani; Gavin Giovannoni; David Bates; Belinda Kemball; Steve Hughes; John Kerrigan
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Disease-Modifying Therapies for Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis.

Authors:  Marita Zimmermann; Elizabeth Brouwer; Jeffrey A Tice; Matt Seidner; Anne M Loos; Shanshan Liu; Richard H Chapman; Varun Kumar; Josh J Carlson
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

5.  Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in Switzerland.

Authors:  Nadine Schur; Kapil Gudala; Umakanth Vudumula; Sreelatha Vadapalle; Arjun Bhadhuri; Alain Casanova; Nicholas Adlard; Matthias Schwenkglenks
Journal:  Pharmacoeconomics       Date:  2021-04-01       Impact factor: 4.981

6.  Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.

Authors:  Timothy Spelman; William L Herring; Thibaut Dort; Yuanhui Zhang; Michael Tempest; Isobel Pearson; Ulrich Freudensprung; Carlos Acosta; Robert Hyde; Eva Havrdova; Dana Horakova; Maria Trojano; Giovanna De Luca; Alessandra Lugaresi; Guillermo Izquierdo; Pierre Grammond; Pierre Duquette; Raed Alroughani; Eugenio Pucci; Franco Granella; Jeannette Lechner-Scott; Patrizia Sola; Diana Ferraro; Francois Grand'Maison; Murat Terzi; Csilla Rozsa; Cavit Boz; Raymond Hupperts; Vincent Van Pesch; Celia Oreja-Guevara; Anneke van der Walt; Vilija G Jokubaitis; Tomas Kalincik; Helmut Butzkueven
Journal:  Pharmacoeconomics       Date:  2021-12-18       Impact factor: 4.981

7.  Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China.

Authors:  Yan Xu; Ningying Mao; Viktor Chirikov; Fen Du; Yu-Chen Yeh; Li Liu; Ruiqi Liu; Xin Gao
Journal:  Clin Drug Investig       Date:  2019-03       Impact factor: 2.859

8.  Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model.

Authors:  Ingrid E H Kremer; Mickael Hiligsmann; Josh Carlson; Marita Zimmermann; Peter J Jongen; Silvia M A A Evers; Svenja Petersohn; Xavier G L V Pouwels; Nick Bansback
Journal:  Med Decis Making       Date:  2020-11       Impact factor: 2.583

Review 9.  How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review.

Authors:  Anggie Wiyani; Lohit Badgujar; Vivek Khurana; Nicholas Adlard
Journal:  Neurol Ther       Date:  2021-07-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.